


ITOC 2

2ND IMMUNOTHERAPY OF CANCER CONFERENCE

25 - 27 MARCH 2015 | MUNICH, GERMANY

PROGRAMME BOOK



© Pseudolongino | Dreamstime.com

www.itoc-conference.eu

IN PARTNERSHIP:



EUROPEAN
CANCER
ORGANISATION



TABLE OF CONTENTS

WELCOME LETTER	5
CANCER DRUG DEVELOPMENT FORUM (CDDF)	6
ORGANISING PARTNERS	7
ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)	7
CONFERENCE COMMITTEE	7
PROGRAMME AT A GLANCE	9
SCIENTIFIC PROGRAMME	10
POSTERS	15
EXHIBITION FLOOR PLAN	17
ACKNOWLEDGEMENT	18
GENERAL INFORMATION	19
SATELLITE SYMPOSIA	22



The Cancer Drug Development Forum (CDDF)
is pleased to welcome you to its 2nd
ImmunoTherapy Of Cancer conference (ITOC-2)
JOIN US AT NEXT YEAR'S ITOC-3!

ITOC 3



SAVE THE DATE

21-23

March 2016

MUNICH, GERMANY



Visit our websites at:

www.cddf.org

www.itoc-conference.eu

Certainly we cannot treat all tumor types.
But we are broadening the horizon of
cancer treatment.

Immuno-Oncology by Bristol-Myers Squibb



Bristol-Myers Squibb



Immuno-Oncology

immunooncology.com

Thursday 26 March 2015, 13:00 – 14:00

Klinikum rechts der Isar, TU Munich, Hörsaal A, Ismaninger Straße 22, 81675 Munich – Germany

Broadening the horizon of Immuno-Oncology in 2015: Melanoma, lung cancer, and beyond

Chair: Christian Peschel (Munich, Germany)

- | | |
|----------------------|--------------------------------------------------------------------------------------------------------------------------|
| 13:00 – 13:20 | Immuno-Oncology:
Raising the bar in melanoma treatment
<i>Winald Gerritsen (Nijmegen, Netherlands)</i> |
| 13:20 – 13:40 | PD-1 inhibition in lung cancer:
Paving the way for a brighter future
<i>Peter Brossart (Bonn, Germany)</i> |
| 13:40 – 14:00 | Immuno-Oncology:
Changing the landscape of cancer therapy?
<i>Peter Johnson (Southampton, UK)</i> |

WELCOME LETTER

Welcome to the second edition of the Immunotherapy of Cancer Conference (ITOC-2).

This meeting is growing rapidly into a global platform for translational research in the field of immuno-oncology. Organized by the Cancer Drug Development Forum, whose mission is to provide a unique platform to facilitate interactions between all stakeholders (academia, regulatory authorities, policymakers, industry, patient advocacy groups and health technology assessors) to improve the efficiency of cancer drug development, the ITOC conference series aims to provide a forum for discussion of early clinical drug development and address its unique challenges.

For this second edition, the conference again has surpassed our expectations in terms of attendance and participants. Our excellent scientific programme with an international faculty will focus on many topics such as immunomodulatory agents, anti-cancer vaccines, adoptive and engineered T-cell Therapy and monoclonal antibodies with special emphasis on translational research and biomarker development.

This week will offer you a broad and exciting range of opportunities and tools to have exposure to experts in various disciplines within Europe and far beyond, and we wish you a very successful and enjoyable ITOC-2 in the beautiful city of Munich. In addition, we wish to express our sincere gratitude to the entire committee, organising partners and sponsors and exhibitors.

Your ideas and suggestions on the future of this conference are welcome, therefore we encourage you to complete the evaluation form after the conference and please do not hesitate to reach out to our team onsite or via info@itoc-conference.eu.

Yours sincerely



Professor Volkmar Nüssler
Conference President



Professor Heinz Zwierzina
Scientific Chair

CANCER DRUG DEVELOPMENT FORUM (CDDF)



The Cancer Drug Development Forum (CDDF) is a not-for-profit organisation registered in Austria.

It was founded in 2001 as Biotherapy Development Association (BDA) and changed its name in 2014 to Cancer Drug Development Forum (CDDF).

While BDA focus was initially around immunotherapy, in recent years the association has embraced all forms of cancer drug development and therefore wanted a name that better reflects the organization breadth of interests.

CDDF provides a unique forum where all those dedicated to the development of cancer drugs can together exchange expertise to find the ways to expedite effective oncology drug development and delivery.


For the past 14 years, CDDF has strived to leverage the discussion of the most promising advances in oncology drug development, uniting experts from academia, pharmaceutical industry and regulatory authorities in the quest of overcoming the main challenges in cancer treatment.

Learn more about CDDF at www.cddf.org.



NORTHWEST BIOTHERAPEUTICS

DCVAX® PERSONALIZED DENDRITIC CELL IMMUNE THERAPIES



Applicable for All Types of Solid Tumors

- DCVax-L for operable tumors
- DCVax-Direct for inoperable tumors

Targets Full Set of Tumor Biomarkers

- Impedes tumor escape

Substantial Patient Survival Extensions

- Long-term survivors in clinical trials to-date

Excellent Safety Profile

- Few SAEs in 10+ years of trials

Solid Manufacturing Infrastructure

- 3-5 Years of personalized doses in 8 days
- Stored and shipped frozen

DCVax® has not yet been approved for commercial distribution by the FDA or EMA.

ORGANISING PARTNERS



EUROPEAN
CANCER
ORGANISATION



ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)



An application for accreditation has been submitted to the European Accreditation Council for CME (EACCME) of the European Union of Medical Specialists (UEMS). The Accreditation Council of Oncology in Europe (ACOE), in partnership with the UEMSEACCME, will review and evaluate the event on the basis of the UEMS-EACCME quality criteria.

CONFERENCE COMMITTEE

Conference Presidents

- Alexander M.M. Eggermont (France)
- Volkmar Nüssler (Germany)
- Mario Sznol (United States)

Scientific Committee

- | | |
|--------------------------------------------------------------------|-----------------------------------|
| ■ Heinz Zwierzina (Austria) - Scientific Programme Committee Chair | ■ Robert Hawkins (United Kingdom) |
| ■ Paolo A. Ascierto (Italy) | ■ Volker Heinemann (Germany) |
| ■ Lisa H. Butterfield (United States) | ■ Samir Khleif (United States) |
| ■ Angus Dalglish (United Kingdom) | ■ Pedro Romero (Switzerland) |
| ■ Stefan Endres (Germany) | ■ Jose Saro (Switzerland) |
| ■ Bernard A. Fox (United States) | ■ Wenru Song (China) |
| ■ Leif Hakansson (Sweden) | ■ Jean Viallet (United States) |
| ■ Jens Hasskarl (Switzerland) | ■ Verena Voelter (Switzerland) |

Abstract Review Committee

- Volkmar Nüssler (Germany) – Abstract Chair
- Sebastian Kobold (Germany)
- Robert Hawkins (United Kingdom)
- Angus Dalglish (United Kingdom)

CARs and Cell Therapy: Today and the Road Ahead

SATELLITE SYMPOSIUM

**SAVE THE DATE:
Friday 27 March 2015
13:00-14:00**

Hörsaal A, Klinikum rechts der Isar
TU Munich
Ismaninger Str. 22
81675 Munich – Germany

PROGRAM

13:00 – 13:05

Welcome

Marcela Maus, MD, PhD, Translational Research Program,
Abramson Cancer Center,
University of Pennsylvania, USA

13:05 – 13:20

The Development and Clinical Experience of CTL019

Marcela Maus, MD, PhD, Translational Research Program,
Abramson Cancer Center,
University of Pennsylvania, USA

13:20 – 13:35

Evolving CAR Therapies in Europe

Hinrich Abken, MD, Center for Molecular Medicine Cologne and
Department I for Internal Medicine,
University Hospital Cologne, Cologne, Germany

13:35 – 13:50

Cell & Gene Therapies of the Future: Novartis Portfolio

Michael S. Perry, DVM, PhD, FRCVS, Chief Scientific Officer,
Cell & Gene Therapy Unit,
Novartis Pharmaceuticals Corporation, USA

13:50 – 14:00

Q & A Panel Session

PROGRAMME AT A GLANCE

TIME	TUESDAY, 24 MARCH	WEDNESDAY, 25 MARCH	THURSDAY, 26 MARCH	FRIDAY, 27 MARCH
				8:00
		9:00	9:00	SATELLITE SYMPOSIUM Checkpoint inhibition: Transforming breakthrough science into better patient care
			10:30	9:00
		10:30	10:30	PLENARY SESSION 7 Adoptive T-Cell Therapy
		12:30	11:00	10:30
		13:30	12:15	Coffee Break
		14:30	13:00	PLENARY SESSION 8 Engineered T cell Therapy
		16:00	14:00	12:30
		16:30	15:10	Lunch
		18:00	15:30	13:00
		19:00	17:00	SATELLITE SYMPOSIUM CARs and Cell Therapy: Today and the Road Ahead
16:00	CDDF BIOMARKER FOR IMMUNOTHERAPY INITIATIVE (BY INVITATION ONLY)		18:30	14:00
19:00				Closing remarks

SCIENTIFIC PROGRAMME

WEDNESDAY, 25 MARCH

10:30	INTRODUCTION Heinz Zwierzina, Innsbruck University, Austria
10:45	KEYNOTE LECTURE: COMBINING IMMUNOMODULATORY AND/OR TARGETED AGENTS Alexander Eggermont, Institut Gustav Roussy, France
11:10	PLENARY SESSION 1: IMMUNE SUPPRESSION AND MICROENVIRONMENT Chairs: Alexander Eggermont and Heinz Zwierzina INTRATUMORAL HETEROGENEITY OF IMMUNOCOMPETENT CELLS Marco Gerlinger, Institute of Cancer Research, United Kingdom RELATIONSHIP BETWEEN MUTATIONAL DENSITY AND RESPONSE TO IMMUNOTHERAPY Timothy Chan, Memorial Sloan Kettering Cancer Center, USA IN VIVO DISCOVERY OF IMMUNOTHERAPY TARGETS IN THE TUMOR ENVIRONMENT Kai Wucherpennig, Dana-Farber Cancer Institute, USA
12:30	LUNCH
13:30	SATELLITE SYMPOSIUM: CANCER IMMUNOTHERAPY: TRANSLATING INNOVATIVE SCIENCE INTO CLINICAL TRIALS
14:30	PLENARY SESSION 1 (CONTINUED): IMMUNE SUPPRESSION AND MICROENVIRONMENT Chairs: Mario Sznol and Samir Khleif THE ROLE OF AN INFLAMMATORY MICROENVIRONMENT FOR MELANOMA METASTASIS AND THERAPY RESISTANCE Thomas Tüting, Bonn University, Germany ROLE OF EXOSOMES IN IMMUNE SUPPRESSION Licia Rivoltini, IRCCS, Italy ANTI-TUMOUR RESPONSE BY RADIOTHERAPY Philipp Beckhove, Heidelberg University, Germany PROFFERED PAPER: ROLE OF SIGNAL TRANSDUCTION AND MICRORNAS ON THE IMMUNOGENICITY OF MELANOMA CELLS Barbara Seliger, Martin Luther University Halle-Wittenberg, Germany PROFFERED PAPER: IMAGING IN CANCER IMMUNOLOGY: PHENOTYPING OF MULTIPLE IMMUNE CELL SUBSETS IN-SITU IN FFPE TISSUE SECTIONS Bjoern Wendik, Germany
16:00	COFFEE BREAK

16:30 **PLENARY SESSION 2 : CHECKPOINT INHIBITION**

Chairs: Pedro Romero and Wenru Song

THERAPY OF ADVANCED CANCER BASED ON IMMUNE CHECKPOINT BLOCKADE

Mario Sznol, Yale Cancer Center, USA

PD-L1 AS A MARKER FOR RESPONSIVENESS TO PD-1/PD-L1 BLOCKADE

Janis Taube, Johns Hopkins University, USA

ROLE OF CHECKPOINT INHIBITORS IN HEMATOLOGIC MALIGNANCIES

Willemijn Hobo, Radboud University, Netherlands

PROFFERED PAPER: IDENTIFICATION OF SECOND-GENERATION POTENT AND SELECTIVE INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE-1 (IDO1)

Juan Jaen, USA

PROFFERED PAPER: A NEW FUSION RECEPTOR OVERCOMES PD-1-MEDIATED IMMUNOSUPPRESSION IN ADOPTIVE T CELL THERAPY

Sebastian Kobold, Klinikum Der Ludwig-Maximilians University, Germany

18:10 -19:00 **WELCOME RECEPTION AND POSTER VIEWING**

THURSDAY, 26 MARCH

09:00 **PLENARY SESSION 3 : COMBINATION THERAPY**

Chairs: Bernie Fox and Volker Heinemann

RATIONALE FOR COMBINATION STRATEGY IN IMMUNOTHERAPY

Pedro Romero, Ludwig Center for Cancer Research, Switzerland

COMBINATION OF ANTI-CANCER VACCINES AND CHECKPOINT INHIBITORS

Samir Khleif, GRU Cancer Center, USA

COMBINATION OF CHECKPOINT INHIBITORS WITH ANTI-ANGIOGENIC AGENTS

Hans Joerg Hammers, Johns Hopkins University, USA

SEQUENCING OR COMBINATION APPROACHES IN IMMUNOTHERAPY

Paolo Ascierto, National Tumor Institute Fondazione Naples, Italy

PROFFERED PAPER: VIROTHERAPY OVERCOMES TUMOR RESISTANCE TO PD1-IMMUNOTHERAPY BY BROAD MUTANOME-DIRECTED T CELL RESPONSES

Woller Norman, Hannover Medical School, Germany

10:35 **COFFEE BREAK**

11:00 **PLENARY SESSION 4 : IMMUNOMODULATORY AGENTS**

Chair: Paolo Ascierto

RATIONALE OF INTEGRATING IMIDS INTO CANCER IMMUNOTHERAPY APPROACHES

Angus Dalgleish, St George's University of London, United Kingdom

IMMUNOMODULATION AND THE ROLE OF THE MICROENVIRONMENT IN LYMPHOMA

Alan Ramsay, Kings College, United Kingdom

CEA TCB: A NOVEL T-CELL BISPECIFIC ANTIBODY FOR THE TREATMENT OF SOLID TUMORS

Marina Bacac, Roche-Glycart, Switzerland

PROFFERED PAPER: IMMUNOMODULATORY CHARACTERISTICS OF RESMINOSTAT, A NOVEL HDAC INHIBITOR IN PHASE II CLINICAL DEVELOPMENT

Svetlana Hamm, Germany

12:15 LUNCH BREAK

13:00 SATELLITE SYMPOSIUM: BROADENING THE HORIZON OF IMMUNO-ONCOLOGY IN 2015: MELANOMA, LUNG CANCER AND BEYOND

14:00 PLENARY SESSION 5 : ANTI-CANCER VACCINES

Chairs: Angus Dalgleish and George Coukos

IMPROVING CANCER VACCINE EFFICACY: WHAT IS NEEDED?

Denise Nardelli-Haeffliger, Lausanne University Hospital, Switzerland

MANIPULATIONS OF THE TUMOR MICROENVIRONMENT BY DENDRITIC CELL VACCINES

Carl Figdor, Radboud University, Netherlands

PROFFERED PAPER: PROLONGED SURVIVAL FOR PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME WHO ARE TREATED WITH TUMOR LYSATE-PULSED AUTOLOGOUS DENDRITIC CELLS

Marnix Bosch, USA

PROFFERED PAPER: A METHOD FOR DEVELOPING PREDICTIVE TESTS FOR IMMUNOTHERAPY BENEFIT

Heinrich Roder, USA

15:10 COFFEE BREAK

15:30 PLENARY SESSION 6 : MONITORING OF IMMUNOTHERAPY

Chairs: Lisa Butterfield and Leif Hakansson

UNEXPECTED TREG, MDSC AND CYTOKINE RESPONSES

Lisa Butterfield, University of Pittsburgh, USA

RECRUITMENT OF INFLAMMATORY CELLS TO TUMOURS – IMPORTANCE OF VASCULAR ENDOTHELIUM MODULATION

George Coukos, Ludwig University, Switzerland

T CELL THERAPY OF MELANOMA; WHAT WE GIVE AND WHAT WE GET!

Per thor Straten, Centre for Cancer Immunotherapy, Denmark

EVALUATION OF TIL IN BREAST CANCER: CURRENT PERSPECTIVE

Bohuslav Melichar, Palacký University Medical School & Teaching Hospital, Czech Republic

16:50 – 18:00 POSTER VIEWING

FRIDAY, 27 MARCH

08:00 **SATELLITE SYMPOSIUM: CHECKPOINT INHIBITION: TRANSFORMING BREAKTHROUGH SCIENCE INTO BETTER PATIENT CARE**

09:00 **PLENARY SESSION 7: ADOPTIVE T-CELL THERAPY**

Chairs: Carl Figdor and Per Thor Straten

IDENTIFICATION OF TUMOR SPECIFIC TIL BY EXOME AND T CELL RECEPTOR SEQUENCING

Jim Yang, NCI, USA

POTENTIAL ROLE OF NKT CELLS IN ADOPTIVE CELL THERAPY

Mark Exley, University Manchester, United Kingdom

PREDICTORS OF TIL EFFICACY IN MELANOMA

Michal Besser, Sheba Medical Center, Israel

COMBINATION OF CHECKPOINT INHIBITORS AND CELL THERAPY

Jeff Webber, Moffit Cancer Centre, USA

10:30 **COFFEE BREAK**

11:00 **PLENARY SESSION 8 : ENGINEERED T CELL THERAPY**

Chairs: Robert Hawkins and Jim Yang

KEYNOTE LECTURE: CHIMERIC ANTIGEN RECEPTOR-ENGINEERED T CELLS FOR CANCER IMMUNOTHERAPY

Marcela Maus, University of Pennsylvania, USA

SOLID TUMOURS

Ulf Petrusch, USZ Zürich, Switzerland

TARGET IDENTIFICATION AND VALIDATION

Dominique Bonnet, Cancer Research UK, United Kingdom

A PLATFORM COMBINING THE WORLD OF BITES AND CARS

Michael Bachmann, Helmholtz-Zentrum Dresden, Germany

12:30 **LUNCH**

13:00 **SATELLITE SYMPOSIUM: CARS AND CELL THERAPY – TODAY AND THE ROAD AHEAD**

14:00 **AWARDS CEREMONY AND CLOSING REMARKS**

Cancer immunotherapy:

Translating innovative science into clinical trials

Wednesday 25 March 2015

13.30–14.30

Main auditorium

Technical University of Munich

Germany

Programme

Chair: *Dirk Jäger, Heidelberg, Germany*

Time	Title
13.30–13.35	Welcome <i>Dirk Jäger, Heidelberg, Germany</i>
13.35–13.50	The interplay between cancer and the immune system <i>Aurélien Marabelle, Villejuif, France</i>
13.50–14.00	Advances in cancer immunotherapy and the role of biomarkers <i>Priti Hegde, Genentech, USA</i>
14.00–14.10	New considerations in clinical trial design <i>Dirk Jäger, Heidelberg, Germany</i>
14.10–14.30	Panel discussion <i>All faculty</i>

POSTERS

Posters are on display in the pavilion throughout the conference. Poster abstracts and author details are listed in the ITOC-2 Abstract Supplement.

MICROENVIRONMENT AND INFLAMMATION

- ITOC2 - 001 Influence of tumor cell – fibroblast co-culture on monocyte differentiation and tumor growth in pancreatic cancer
- ITOC2 - 002 Immunosuppressive microenvironment in pancreatic adenocarcinoma
- ITOC2 - 003 Store-operated calcium signaling in EGF-mediated COX-2 inflammatory gene activation in cancer cells
- ITOC2 - 005 Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections
- ITOC2 - 006 Humanized mouse models for preclinical testing of antitumor immune therapy
- ITOC2 - 007 Notch triggers myeloid reprogramming in murine pancreatic cancer

IMMUNOSUPPRESSION

- ITOC2 - 008 Two immune faces of pancreatic adenocarcinoma: Impact of immunosuppression
- ITOC2 - 009 Melanoma differentiation-associated protein 5 (MDA5)-based tumor immunotherapy reprograms M2/G2-polarized myeloid-derived suppressor cells (MDSCs)
- ITOC2 - 010 Role of signal transduction and microRNAs on the immunogenicity of melanoma cells

THERAPEUTIC MODULATION OF IMMUNE CHECKPOINTS

- ITOC2 - 011 Virotherapy overcomes tumor resistance to PD1-immunotherapy by broad mutanome-directed T cell responses
- ITOC2 - 012 Identification of Second-Generation Potent and Selective Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1) for the Treatment of Cancer
- ITOC2 - 013 Neoadjuvant immune checkpoint blockade for pancreatic cancer prevents local tumor recurrence through tissue resident antitumoral CD8+ CD103+ T cells
- ITOC2 - 014 In vitro kynurenine modulation by novel dual-acting and selective TDO and IDO inhibitors
- ITOC2 - 015 Immunomodulation of blasts in AML-Patients (PTS) with clinically approved response modifiers to improve antileukemic T-cell reactivity: An ex vivo simulation of the clinical
- ITOC2 - 016 Therapy of hepatocellular carcinoma (HCC) with immunostimulatory RNA activating RIG-I

ANTI-CANCER VACCINES

- ITOC2 - 017 Effective vaccination against melanoma in an animal study: Combination of laser-assisted dermal skin delivery and cross-presenting XCR1+ dermal DCs targeting
- ITOC2 - 018 Prolonged Survival for Patients with Recurrent Glioblastoma Multiforme who are Treated with Tumor Lysate-Pulsed Autologous Dendritic Cells
- ITOC2 - 019 Hyperthermia induced immunogenic cell-death

- ITOC2 - 020 An open-label multicenter phase II trial of aviscumine in previously treated patients with unresectable stage IV metastatic melanoma
- ITOC2 - 021 VGX-3100 Immunotherapy for CIN2/3 Induces Regression of Cervical Lesions and Viral Clearance (Phase II Study): Implications for Treatment of HPV Associated Cancers
- ITOC2 - 022 The melanoma immune-peptidome for T-cell-based anti-tumor immunotherapies
- ITOC2 - 023 Vaccination with next-generation dendritic cells for AML postremission therapy induces antigen-specific T cell responses
- ITOC2 - 024 Integrated computational pipeline for development of personalised melanoma vaccine

ANTIBODY THERAPY

- ITOC2 - 025 Selective lysis of biphenotypic leukemia cells is mediated by dual-targeting triplebody 33-3-19 treatment

ENGINEERED T-CELL THERAPY

- ITOC2 - 027 A new fusion receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy
- ITOC2 - 028 Redirecting adenovirus-specific T cells by a tumor-specific T cell receptor for therapy of hepatocellular carcinoma
- ITOC2 - 029 Transgenic antigen-specific, allogeneic HLA-A*0201-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity


COMBINATION THERAPY

- ITOC2 - 030 Combination of CTLA4-blockade, depletion of CD25+ cells and active-specific immunotherapy prolongs survival in murine melanoma
- ITOC2 - 031 Combination therapy Identification of the neoantigen Ndufs1-V491A for investigations on immunotherapies in murine tumor models
- ITOC2 - 032 Combination therapy Immunomodulatory characteristics of Resminostat, a novel HDAC inhibitor in phase II clinical development
- ITOC2 - 033 Optimizing active-specific immunotherapy in lymphodepleted mice with subcutaneous melanoma

MONITORING OF IMMUNOTHERAPY

- ITOC2 - 034 Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma
- ITOC2 - 035 Development of a 3D cell culture model for the investigation of cancer cell/immune cell interactions
- ITOC2 - 036 The immunotherapeutic TLR-9 agonist MGN1703 – Pharmacokinetic and pharmacodynamic data from healthy volunteers and cancer patients
- ITOC2 - 037 A method for developing predictive tests for immunotherapy benefit

EXHIBITION FLOOR PLAN



ACKNOWLEDGEMENT

The conference is very grateful to the following companies for their generous support to ITOC-2

PLATINUM SPONSORS



SILVER SPONSOR



EDUCATIONAL GRANT



GENERAL INFORMATION

SECRETARIAT

Cancer Drug Development Forum
c/o ECCO – the European CanCer Organisation
Avenue E. Mounier, 83
B-1200 Brussels Belgium
Tel.: +32 (0) 2 775 02 01
Fax: + 32 (0) 2 775 02 00 E

CONFERENCE VENUE

Hörsaal A (Auditorium A)

Klinikum Rechts der Isar
Entrance Einstein Strasse
TU Munich Ismaninger Str. 22
81675 Munich

HOW TO GET TO THE VENUE

The Klinikum Rechts der Isar is very accessible by public transport. From the Hilton Munich City (ITOC-2 official hotel), take tram 16 from tram stop Am Gasteig in the direction of Max-Weber-Platz.

The Klinikum is also reachable by U-bahn U4 and U5 – station Max-Weber-Platz.

Please note that the best entrance of the conference is not the Klinikum main entrance on Ismaninger Strasse. The conference is best accessed via the entrance on the Einstein Strasse, as indicated below.





Discover PD-1: An immune checkpoint pathway¹

Artist's interpretation based on scanning electron microscopy.

Some tumor cells can evade the body's immune response, which may result in disease progression^{2,3}

- One function of the body's immune response is to detect and destroy tumor cells through activated T cells and other mechanisms; tumor cells express multiple antigens that are not expressed in normal tissue.¹⁻³
- However, some tumor cells may evade the body's immune response by exploiting the PD-1 checkpoint pathway through expression of the dual PD-1 ligands PD-L1 and PD-L2.^{1,2,4-7}
- PD-L1 and PD-L2 engage the PD-1 receptor on T cells in order to inactivate T cells, which may allow tumor cells to evade the immune response.^{1,2,8}

MSD is committed to furthering the understanding of immunology in cancer, including the role of the PD-1 pathway.

Visit the MSD booth to learn more.

PD-1=programmed cell death protein 1; PD-L1=programmed cell death ligand 1; PD-L2=programmed cell death ligand 2.

References: **1.** Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer*. 2012;12(4):252–264. **2.** Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. *Annu Rev Immunol*. 2008;26:677–704. **3.** Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646–674. **4.** Quezada SA, Peggs KS. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. *Br J Cancer*. 2013;108(8):1560–1565. **5.** Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. *Nat Rev Immunol*. 2008;8(6):467–477. **6.** Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *J Exp Med*. 2003;198(6):851–862. **7.** Nomi T, Shio M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. *Clin Cancer Res*. 2007;13(7):2151–2157. **8.** Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. *Nat Immunol*. 2001;2(3):261–268.



Registration

ITOC-2 is open to all registered participants. Your official delegate name badge is required for admission to the conference centre and all conference events. For security reasons, participants are requested to wear their badge at all times.

Registration Opening Hours

WEDNESDAY, 25 MARCH	8:00 - 18:00
THURSDAY, 26 MARCH	8:00 - 18:00
FRIDAY, 27 MARCH	8:00 - 11:00

Registration Fees

FULL CONGRESS	
ACADEMIA REGISTRATION	600€
INDUSTRY REGISTRATION	850€
STUDENT REGISTRATION*	175€

**appropriate and valid student identification has to be provided*

ONE DAY CONGRESS	
ACADEMIA REGISTRATION	175€
INDUSTRY REGISTRATION	275€

Badges

For security reasons, delegates are requested to wear their badge at all times during the conference. Delegates having lost their badge can obtain a new badge at the registration desk. A replacement fee may be charged.

Lost & Found

All enquiries should be directed to the registration desk in the entrance hall. The organisers accept no responsibility for loss due to theft or negligence.

Catering

Coffee breaks, lunches and a welcome reception courtesy of the organisers have been scheduled and are included in the registration fees. Exact times are listed in the programme overview.

Conference Bag

To receive the conference bag including all conference material, please present the voucher attached to your badge at the bag distribution centre, in the registration area.

Exhibition

The exhibition is held in the foyer of the conference centre. Entrance is free for registered delegates but limited to healthcare professionals, press and exhibitors.

Insurance

The organisers of ITOC-2 do not accept liability for individual medical, travel or personal insurance. Participants are strongly recommended to obtain their own personal insurance policies. The organisers of ITOC-2 accept no responsibility for loss due to theft or negligence.

Language & Translation

The official language of the conference is English. No simultaneous translation is provided.

POLICIES

ITOC-2 is accessible to all registered delegates. Children and members of the public are not permitted in the exhibition area or any room hosting an industry activity. In addition, the ITOC-2 Conference asks delegates and faculty to refrain from taking children and accompanying adults to any scientific sessions or practical demonstrations. In the event that children are required to enter the conference centre they should be supervised by an adult at all times and observe the restrictions that apply to limited access areas. In the event that a member of public is invited to participate in the ITOC Conference scientific programme, they should be accompanied by a qualified healthcare professional or ITOC representative observing the ITOC restrictions where appropriate.

SATELLITE SYMPOSIA

WEDNESDAY, 25 MARCH

Roche

13.30–14.30 **CANCER IMMUNOTHERAPY: TRANSLATING INNOVATIVE SCIENCE INTO CLINICAL TRIALS**

WELCOME

Prof. Dirk Jäger, Germany

THE INTERPLAY BETWEEN CANCER AND THE IMMUNE SYSTEM

Aurélien Marabelle, France

ADVANCES IN CANCER IMMUNOTHERAPY AND THE ROLE OF BIOMARKERS

Dr. Priti Hegde, USA

NEW CONSIDERATIONS IN CLINICAL TRIAL DESIGN

Prof. Dirk Jäger, Germany

PANEL DISCUSSION

All faculty

THURSDAY, 26 MARCH



Bristol-Myers Squibb

13:00 – 14:00 **BROADENING THE HORIZON OF IMMUNO-ONCOLOGY IN 2015: MELANOMA, LUNG CANCER AND BEYOND**

Chair: Professor Christian Peschel (Munich, Germany)

IMMUNO-ONCOLOGY: RAISING THE BAR IN MELANOMA TREATMENT

Winald Gerritsen, Netherlands

NEW ERA OF THERAPY?

Peter Brossart, Germany

IMMUNO-ONCOLOGY: CHANGING THE LANDSCAPE OF CANCER THERAPY?

Peter Johnson, United Kingdom

FRIDAY, 27 MARCH



08:00 – 09:00 CHECKPOINT INHIBITION: TRANSFORMING BREAKTHROUGH SCIENCE INTO BETTER PATIENT CARE

Chair: Dirk Schadendorf, Germany

INTRODUCTION AND OPENING REMARKS

Dirk Schadendorf, Germany

CLINICAL INSIGHTS: CHECKPOINT INHIBITOR THERAPY ACROSS THE SPECTRUM OF ADVANCED MELANOMA

Dirk Schadendorf, Germany

CLINICAL INSIGHTS: NEW APPROACHES WITH CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED NSCLC

Rolf Stahel, Switzerland

PANEL DISCUSSION BASED ON CASE STUDY (2ND LINE PATIENT): HOW DO WE MOST EFFECTIVELY INTEGRATE ANTI-PD-1 THERAPIES INTO CLINICAL PRACTICE?

Faculty

CLOSING REMARKS



13:00 – 14:00 CARS AND CELL THERAPY: TODAY AND THE ROAD AHEAD

WELCOME AND INTRODUCTIONS

Marcela Maus, USA

THE DEVELOPMENT AND CLINICAL EXPERIENCE OF CTL019

Marcela Maus, USA

EVOLVING CAR THERAPIES IN EUROPE

Hinrich Abken, Germany

CELL & GENE THERAPIES OF THE FUTURE: PRODUCTS IN DEVELOPMENT AT NOVARTIS

Mike Perry, USA

QUESTION AND ANSWER SESSION

ITOC 2

2ND IMMUNOTHERAPY OF CANCER CONFERENCE

25 - 27 MARCH 2015 | MUNICH, GERMANY



**Cancer Drug Development Forum
c/o ECCO – the European CanCer Organisation**

Avenue E. Mounier, 83

B-1200 Brussels Belgium

Tel.: +32 (0) 2 775 02 01

Fax: + 32 (0) 2 775 02 00

Email: info@itoc-conference.eu

www.itoc-conference.eu

IN PARTNERSHIP:



EUROPEAN
CANCER
ORGANISATION

